Lixte Biotechnology Holdings, Inc. Common Stock
LIXTLixte Biotechnology Holdings, Inc. is a biotechnology company focused on the discovery and development of targeted therapies for cancers and neurological disorders. The company utilizes its proprietary drug discovery platform to identify small-molecule compounds aimed at specific disease targets, with an emphasis on developing novel treatments with potential for clinical application.
Company News
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage biotech company, announced a definitive agreement to acquire NOMAD Transportable Power Systems and rebrand as NOMAD Power Solutions. The move positions the company to capitalize on a critical infrastructure gap: while data centers can be built in months, grid connections take 5-7 years...
LIXTE Biotechnology announced its participation in the DealFlow Discovery Conference on January 28-29, 2026, where CEO Geordan Pursglove will meet with investors. The company is advancing LB-100, a first-in-class PP2A inhibitor for cancer treatment, with proof-of-concept trials underway for ovarian clear cell carcinoma, metastatic colon cancer, a...
Spartan Capital Securities acted as exclusive placement agent for Lixte Biotechnology Holdings' $4.3 million registered direct offering. The clinical-stage pharmaceutical company focused on cancer treatments sold 1,051,342 common and pre-funded units to accredited investors at market prices, with proceeds to support general corporate purposes and...
LIXTE Biotechnology is advancing its cancer therapy pipeline with LB-100, a protein phosphatase 2A inhibitor targeting ovarian clear cell carcinoma, soft tissue sarcoma, and metastatic colon cancer, with potential trial results expected in late 2025.
LIXTE Biotechnology Holdings, Inc. has filed a request to withdraw its Registration Statement on Form S-1, as the company no longer intends to pursue a public offering at this time.
